Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: Evidence for an immune etiology

Thrombosis and Haemostasis

Volumn 88, Issue 6, 2002, Pages 892-897

  Brassard, Jacqueline A ^c   Curtis, Brian R ^a   Cooper, Richard A ^b   Ferguson, John ^c   Komocsar, Wendy ^c   Ehardt, Maria ^a,b,c,d   Kupfer, Stuart ^c   Maurath, Clement ^c   Swabb, Edward ^c   Cannon, Christopher P ^d   Aster, Richard H ^a,b  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c PFIZER INC   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antibodies; GPIIb IIIa inhibitors; Platelets

Indexed keywords

ABCIXIMAB; ANTIBODY; DRUG ANTIBODY; FIBAN DEPENDENT ANTIBODY; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; IMMUNOGLOBULIN; ORBOFIBAN; PLACEBO; TICLOPIDINE; UNCLASSIFIED DRUG; XEMILOFIBAN;

ACUTE DISEASE; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BLEEDING; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOLOGY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK ASSESSMENT; SEPTICEMIA; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYMPTOM; THROMBOCYTE; THROMBOCYTOPENIA; TRANSFUSION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 12244297766     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613330     Document Type: Article

References (33)

1. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb/IIIa blockers. Lancet 1999; 353: 227-31.
2. Mousa SA. Antiplatelet therapies: Recent advances in the development of platelet glycoprotein IIb/IIIa antagonists. Curr Interv Cardiol Rep 1999; 1: 243-52.
3. Verstraete M. Platelet glycoprotein IIb/IIIa receptor antagonization. Biomed Prog 2000; 13: 27-30.
4. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using Integrilin therapy (PURSUIT) trial experience. Circulation 1999; 99: 2892-900.
5. Llevadot J, Coulter SA, Giugliano RP. A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis 2000; 9: 175-80.
6. Giugliano RP. Drug-induced thrombocytopenia: Is it a serious concern for glycoprotein IIb/IIIa receptor inhibitors? J Thrombo Thrombolysis 1998; 5: 191-202.
7. Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J 1999; 138: 317-26.
8. Cines DB. Glycoprotein IIb/IIIa antagonists: Potential induction and detection of drug-dependent antiplatelet antibodies. Am Heart J 1998; 135: S152-9.
9. Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral Xemilofiban in 170 patients after coronary stent deployment. Circulation 1997; 96: 1117-21.
10. Nicholson NS, Abood NA, Panzer-Knodle SG, et al. Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist. Medicinal Research Reviews 2001; 21: 211-26.
11. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glyco-protein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102: 149-56.
12. O'Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein receptor antagonist after percutaneous coronary revascularization. N Engl J Med 2000; 342: 1316-24.
13. Kereiakes DJ, Kleiman NS, Ferguson JJ, et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glyco-protein IIb/IIIa receptor blockade with oral xemilofiban. Results of a multicenter, placebo-controlled, randomized trial. Circulation 1998; 98: 1268-78.
14. Ferguson JJ, Deedwania DC, Kereiakes DJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral orbofiban: Interin pharmacodynamic results of the SOAR study. J Am Coll Cardiol 1998; 31: 185A (abstract).
15. Curtis BR, McFarland JG, Wu GG, et al. Antibodies associated with sulfonamide-induced immune thrombocytopenia react preferentially with calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994; 84: 176-83.
16. Peterson JA, Visentin GP, Newman PJ, et al. A recombinant soluble form of the integrin alpha IIb (GPIIb/IIIa) assumes an active, ligand-binding conformation and is recog-nized by GPIIb-IIIa-specific monoclonal, allo-, auto-, and drug-dependent platelet antibodies. Blood 1998; 92: 2053-63.
17. Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopenia in a population of high-risk percutaneous coronary revascularization. J Amer Coll Cardiol 1998; 32: 311-9.
18. Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-8.
19. Visentin GP, Malik M, Cyganiak KA, et al. Patients treated with unfractionated heparin during open-heart surgery are at high risk to form antibodies reactive with heparin: Platelet factor 4 complexes. J Lab Clin Med 1996; 128: 376-83.
20. Cox D, Smith R, Quinn M, et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Amer Coll Cardiol 2000; 36: 1514-9.
21. Jubelirer SJ, Koenig BA, Bates MC. Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: Case reports, review of the literature, and implications for therapy. Am J Hematol 1999; 61: 205-8.
22. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
23. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
24. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53.
25. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
26. Aster RH. Drug-induced immune thrombocytopenia: An overview of pathogenesis. Sem Hematol 1999; 36: 2-6.
27. Bednar B, Cook JJ, Holohan MA, et al. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and Rhesus monkey associated with preexisting drug-dependent antibodies to platelet glyco-protein IIb/IIIa. Blood 1999; 94: 587-99.
28. Hongo RH, Brent BN. Association of eptifibatide and acute, profound thrombocytopenia. Amer J Cardiol 2001; 88: 428-31.
29. Paradiso-Hardy FL, Mandan M, Radhakrishnan S, et al. Severe thrombocytopenia possibly related to re-administration of eptifibatide. Catatt Cardiovasc Intervent 2001; 54: 63-7.
30. Frelinger AL III, Lam SC, Plow EF, et al. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem 1988; 263: 12397-402.
31. Jennings LK, Haga JH, Slack SM. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost 2000; 84: 1095-102.
32. Guigliano RP, McCabe SH, Sequiera RF et al. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of the TIMI 15A and 15B trials. Am Heart J 2000; 140: 81-93.
33. Bilheimer JT, Dicker IB, Wynn R et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002; 99: 3540-6.